Systemic Sclerosis Market

Global Systemic Sclerosis Market is segmented By Type (Limited, Diffuse), By Drug Type (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The Global Systemic Sclerosis Market is expected to grow at a CAGR of 6.0% during the forecasting period (2021-2028).

• Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology that affects the skin, blood vessels, muscles, joints, and a variety of internal organs, such as the digestive tract, heart, lungs, and kidneys.

• Global Systemic sclerosis treatment market is estimated to reach USD 1.4 million by 2024.

Market Growth

• Primary market drivers include increased use of expensive biologics, the rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients and new drug approvals.

• However, delay in diagnosis and lack of safe and effective treatments will restrain market growth.

Market Segmentation

• The Global Systemic sclerosis market report segments the market by type, drug type and by region.

• Based on the extent of skin involvement, the market is segmented into Limited cutaneous systemic sclerosis (lcSSc), or limited scleroderma and Diffuse cutaneous systemic sclerosis (dcSSc), or diffuse scleroderma.

• Limited cutaneous systemic sclerosis is the more common type of SSc.

• Based on drug type, the market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors.

• Regarding the drug category, the segment of immunosuppressive agents is expected to retain dominance over the forecast period.

• Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

• North America will dominate the market. The US has an annual incidence of about 20 cases per 1 million adults.

Scope of the Report

• The report profiles the following companies of Systemic sclerosis market – Actelion, Roche/Genentech, BMS, Allergan, GSK, Biogen, Novartis, Teva, MedImmune, Celgene, Chugai, ASTA, Aspen, Pfizer, Eli Lilly, Bayer and many more.

By Type

• Limited

• Diffuse

By Drug Type

• Corticosteroids

• Immunosuppressive Agents

• Endothelin Receptor Agonists

• Calcium Channel Blockers

• Phosphodiesterase 5 Inhibitors

• Chelating Agents

• Prostacyclin Analogues

• H2 Blockers

• Proton Pump Inhibitors

• ACE Inhibitors

By Region

• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

• North America (The USA, Canada, Mexico)

• South America (Brazil, Argentina, Rest of South America)

• Rest of the World

Why purchase the report?

• Visualize the composition of Systemic sclerosis market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.

• Identify commercial opportunities in Systemic sclerosis market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of the market – level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for crucial products of all major market players

Target Audience:

• Equipment Suppliers/ Buyers

• Service Providers/ Buyers

• Industry Investors/Investment Bankers

• Education & Research Institutes

• Research Professionals

• Emerging Companies

• Manufacturers

 

Table of Contents

Chapter 1 – Systemic sclerosis Market – Methodology and Scope

1.1 Research Methodology

1.2 Scope of the Report

Chapter 2 – Systemic sclerosis Market – Trends

2.1 Key Trends & Developments

Chapter 3 - Systemic sclerosis Market – Industry Analysis

3.1 Market Drivers

• Increased use of expensive biologics
• Rise in clinical trials for systemic sclerosis
• High acceptance of new therapies by patients
• New drug approvals
• Market Restraints
• Lack of safe and effective treatments
• Delay in diagnosis

3.2 Threats and Opportunities

• Porter’s 5 Forces

Chapter 4 – Systemic sclerosis Market – Market Analysis

4.1. Systemic sclerosis Market – By Type

• Limited
• Diffuse

4.2 Systemic sclerosis Market – By Drug Type

• Corticosteroids
• Immunosuppressive Agents
• Endothelin Receptor Agonists
• Calcium Channel Blockers
• Phosphodiesterase 5 Inhibitors
• Chelating Agents
• Prostacyclin Analogues
• H2 Blockers
• Proton Pump Inhibitors
• ACE Inhibitors

Chapter 5 - Global Systemic sclerosis Market – Geographical Analysis

5.1. North America

5.1.1. The USA

5.1.2. Canada

5.1.3. Mexico

5.2. Europe

5.2.1. Germany

5.2.2. France

5.2.3. The UK

5.2.4. Italy

5.2.5. Spain

5.2.6. Rest of Europe

5.3. Asia Pacific

5.3.1. China

5.3.2. Japan

5.3.3. India

5.3.4. Australia

5.3.5. Rest of Asia Pacific

5.4. South America

5.4.1. Brazil

5.4.2. Argentina

5.4.3. Rest of South America

5.5 Rest of the World

Chapter 6 - Global Systemic sclerosis Market – Competitive Landscape

6.1. Market Share Analysis

6.2. Mergers and Acquisitions Analysis

6.3. New Product Launches

Chapter 7 - Global Systemic sclerosis Market – Company Profiles

1. Actelion
2. Roche/Genentech
3. BMS
4. Allergan
5. GSK
6. Biogen
7. Novartis
8. Teva
9. MedImmune
10. Celgene
11. Chugai
12. ASTA
13. Aspen
14. Pfizer
15. Eli Lilly
16. Bayer

Chapter 8 -Global Systemic sclerosis Market – Appendix

8.1 Sources

8.2 List of Tables

8.3 Expert Panel Validation

8.4 Disclaimer

8.5 Contact Us